Cells,
Journal Year:
2025,
Volume and Issue:
14(1), P. 41 - 41
Published: Jan. 3, 2025
Despite
the
advances
of
CAR-T
cells
in
certain
hematological
malignancies,
mostly
from
B-cell
derivations
such
as
non-Hodgkin
lymphomas,
acute
lymphoblastic
leukemia
and
multiple
myeloma,
a
significant
portion
other
non-hematological
pathologies
can
benefit
this
innovative
treatment,
results
clinical
studies
are
demonstrating.
The
application
setting
T-lymphoid
leukemia,
myeloid
solid
tumors,
autoimmune
diseases
infections
has
encountered
limitations
that
different
those
diseases.
To
overcome
these
restrictions,
strategies
based
on
molecular
engineering
platforms
have
been
devised
will
be
illustrated
below.
aim
manuscript
is
to
provide
an
overview
than
currently
treated,
highlighting
both
limits
obtained
with
settings.
Nano Letters,
Journal Year:
2021,
Volume and Issue:
22(1), P. 533 - 542
Published: Oct. 20, 2021
Viral
engineered
chimeric
antigen
receptor
(CAR)
T
cell
therapies
are
potent,
targeted
cancer
immunotherapies,
but
their
permanent
CAR
expression
can
lead
to
severe
adverse
effects.
Nonviral
messenger
RNA
(mRNA)
cells
being
explored
overcome
these
drawbacks,
electroporation,
the
most
common
transfection
method,
is
limited
by
cytotoxicity.
As
a
potentially
safer
nonviral
delivery
strategy,
here,
sequential
libraries
of
ionizable
lipid
nanoparticle
(LNP)
formulations
with
varied
excipient
compositions
were
screened
in
comparison
standard
formulation
for
improved
mRNA
low
cytotoxicity,
revealing
B10
as
top
3-fold
increase
delivery.
When
compared
electroporation
primary
human
cells,
LNPs
induced
comparable
reduced
cytotoxicity
while
demonstrating
potent
killing.
These
results
demonstrate
impact
optimization
on
LNP
performance
and
support
platform
engineering.
Advanced Healthcare Materials,
Journal Year:
2023,
Volume and Issue:
12(30)
Published: Aug. 21, 2023
The
programmed
cell
death
protein
1
(PD-1)
signaling
pathway
is
a
major
source
of
dampened
T
activity
in
the
tumor
microenvironment.
While
clinical
approaches
to
inhibiting
PD-1
using
antibody
blockade
have
been
broadly
successful,
these
lead
widespread
suppression,
increasing
risk
autoimmune
reactions.
This
study
reports
development
an
ionizable
lipid
nanoparticle
(LNP)
platform
for
simultaneous
therapeutic
gene
expression
and
RNA
interference
(RNAi)-mediated
transient
knockdown
cells.
In
developing
this
platform,
interesting
interactions
are
observed
between
two
cargoes
when
co-encapsulated,
leading
improved
characteristics
compared
delivering
either
cargo
alone.
messenger
(mRNA)/small
interfering
(siRNA)
co-delivery
adopted
deliver
chimeric
antigen
receptor
(CAR)
mRNA
siRNA
targeting
primary
human
cells
ex
vivo
strong
CAR
without
apparent
changes
overall
activation
state.
delivery
shows
great
promise
immune
modulation
number
immunoengineering
applications,
including
cancer
immunotherapies.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(26)
Published: Feb. 29, 2024
Abstract
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
has
achieved
remarkable
clinical
success
in
the
treatment
of
hematological
malignancies.
However,
producing
these
bespoke
cancer‐killing
cells
is
a
complicated
ex
vivo
process
involving
leukapheresis,
artificial
activation,
and
CAR
construct
introduction.
The
activation
step
requires
engagement
CD3/TCR
CD28
vital
for
transfection
differentiation.
Though
antigen‐presenting
(APCs)
facilitate
vivo,
relies
on
antibodies
against
CD3
conjugated
to
magnetic
beads.
While
effective,
this
adds
complexity
production
as
beads
must
be
removed
prior
implementation.
To
overcome
challenge,
work
develops
activating
lipid
nanoparticles
(aLNPs)
that
mimic
APCs
combine
capabilities
LNPs.
It
shown
aLNPs
enable
one‐step
primary
human
with
resulting
mRNA
reducing
tumor
burden
murine
xenograft
model,
validating
promising
platform
rapid
cells.
Viruses,
Journal Year:
2024,
Volume and Issue:
16(2), P. 219 - 219
Published: Jan. 31, 2024
Chronic
Human
Immunodeficiency
Virus
(HIV)
infection
remains
a
significant
challenge
to
global
public
health.
Despite
advances
in
antiretroviral
therapy
(ART),
which
has
transformed
HIV
from
fatal
disease
into
manageable
chronic
condition,
definitive
cure
elusive.
One
of
the
key
features
is
immune
activation
and
inflammation,
are
strongly
associated
with,
predictive
of,
progression,
even
patients
successfully
treated
with
suppressive
ART.
inflammation
characterized
by
persistent
cell
metabolic
dysregulation,
cellular
exhaustion
dysfunction.
This
review
aims
summarize
current
knowledge
interplay
between
metabolism,
T
dysfunction
infection,
also
discusses
use
humanized
mice
models
study
pathogenesis
develop
novel
therapeutic
strategies.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(19)
Published: Feb. 14, 2024
The
removal
of
dying
cells,
or
efferocytosis,
is
an
indispensable
part
resolving
inflammation.
However,
the
inflammatory
microenvironment
atherosclerotic
plaque
frequently
affects
biology
both
apoptotic
cells
and
resident
phagocytes,
rendering
efferocytosis
dysfunctional.
To
overcome
this
problem,
a
chimeric
antigen
receptor
(CAR)
macrophage
that
can
target
engulf
phagocytosis-resistant
expressing
CD47
developed.
In
normal
circumstances,
CAR
macrophages
exhibit
activity
equivalent
to
antibody
blockage.
surface
modified
with
reactive
oxygen
species
(ROS)-responsive
therapeutic
nanoparticles
targeting
liver
X
pathway
improve
their
cell
effector
activities.
combination
nanoparticle
engineering
activated
lipid
efflux
pumps
enhances
debris
clearance
reduces
It
further
suggested
undifferentiated
CAR-Ms
transmigrate
within
mico-fabricated
vessel
system.
also
shown
our
act
as
switch
(CSR)
withstand
immunosuppressive
environment.
developed
platform
has
potential
contribute
advancement
next-generation
cardiovascular
disease
therapies
studies
include
in
vivo
experiments.
Cellular and Molecular Immunology,
Journal Year:
2020,
Volume and Issue:
18(4), P. 792 - 804
Published: Sept. 30, 2020
Chimeric
antigen
receptor
(CAR)
T-cell
therapy
has
achieved
significant
success
in
the
treatment
of
hematological
malignancies.
In
recent
years,
fast-growing
CAR
T
clinical
trials
have
actively
explored
their
potential
application
scenarios.
According
to
data
from
clinicaltrials.gov
website,
China
became
country
with
most
registered
September
2017.
As
June
30,
2020,
number
reached
357.
addition,
as
many
150
other
been
on
ChiCTR.
Although
is
flourishing
China,
there
are
still
some
problems
that
cannot
be
ignored.
this
review,
we
aim
systematically
summarize
practice
China.
This
review
will
provide
an
informative
reference
for
colleagues
field,
and
a
better
understanding
history
current
situation
help
us
more
reasonably
conduct
research
promote
cooperation.
Cell Discovery,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: May 14, 2024
Chimeric
antigen
receptor
T
(CAR-T)
cells
have
been
proposed
for
HIV-1
treatment
but
not
yet
demonstrated
desirable
therapeutic
efficacy.
Here,
we
report
newly
developed
anti-HIV-1
CAR-T
armed
with
endogenic
broadly
neutralizing
antibodies
(bNAbs)
and
the
follicle-homing
CXCR5,
termed
M10
cells.
were
designed
to
exercise
three-fold
biological
functions,
including
broad
cytotoxic
effects
on
HIV-infected
cells,
neutralization
of
cell-free
viruses
produced
after
latency
reversal,
B-cell
follicle
homing.
After
demonstrating
activities,
administered
treat
18
patients
via
a
regimen
two
allogenic
cell
infusions
an
interval
30
days,
each
infusion
followed
by
chidamide
stimulations
reservoir
activation.
Consequently,
74.3%
resulted
in
significant
suppression
viral
rebound,
loads
declining
average
67.1%,
10
showed
persistently
reduced
cell-associated
RNA
levels
(average
decrease
1.15
log10)
over
150-day
observation
period.
also
found
impose
selective
pressure
latent
reservoir.
No
treatment-related
adverse
observed.
Overall,
our
study
supported
potential
as
novel,
safe,
effective
option
functional
cure
HIV-1/AIDS.
Molecular Therapy,
Journal Year:
2024,
Volume and Issue:
32(4), P. 1000 - 1015
Published: Feb. 27, 2024
Adoptive
cell
therapy
(ACT)
using
T
cells
expressing
chimeric
antigen
receptors
(CARs)
is
an
area
of
intense
investigation
in
the
treatment
malignancies
and
chronic
viral
infections.
One
limitations
ACT-based
CAR
lack
vivo
persistence
maintenance
optimal
function.
Therefore,
alternative
strategies
that
increase
function
CAR-expressing
are
needed.
In
our
studies
humanized
bone
marrow/liver/thymus
(BLT)
mouse
model
nonhuman
primate
(NHP)
HIV
infection,
we
evaluated
two
CAR-based
gene
approaches.
ACT
approach,
used
cytokine
enhancement
preconditioning
to
generate
greater
anti-HIV
